
Zihai Li: Targeting TGFβ Docking Receptor GARP via CAR-T Cell Platform to Treat Glioblastoma
Zihai Li, Professor and Founding Director at the Pelotonia Institute for Immuno-Oncology, shared a post on X about a paper published on Neuro-Oncology:
“This is our preclinical work on targeting TGFβ docking receptor GARP via CAR-T cell platform to treat glioblastoma Our clinical trial is actively enrolling pts. Many thanks to all authors and collaborators to make it possible.”
Title: Targeting TGFβ docking receptor Glycoprotein A Repetitions Predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma
Authors: Bill Xingjun Wu , Daniel Kreatsoulas , Hakan Cam , Chelsea Bolyard , Yuzhou Chang , Jay Mandula , Parker W Welsh , Ziyu Wang , Anqi Li , Payton Weltge , J Bradley Elder , Pierre Giglio , Jose J Otero , Prajwal Rajappa , Damien Gerald , Dongjun Chung , Qin Ma , Maria Velegraki , Zihai Li
Read the full article.
More posts featuring Zihai Li on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023